title: Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still's disease. An open, randomized, multicenter study.
abstract: OBJECTIVE
  To study the efficacy of anakinra versus disease-modifying antirheumatic drugs (DMARD) in refractory adult-onset Still's disease (AOSD).
  
  
  METHODS
  In a 24-week study, 22 patients with AOSD taking prednisolone ≥ 10 mg/day received anakinra (n = 12) or DMARD (n = 10). The primary endpoint was achievement of remission.
  
  
  RESULTS
  At 8 and 24 weeks, 7/12 and 6/12 receiving anakinra and 5/10 and 2/10 receiving DMARD achieved remission. Anakinra induced greater improvement in physical health measured by Medical Outcomes Study Short-Form 36 (SF-36; p < 0.011). During an open-label extension (OLE) of 28 weeks, 7/14 patients taking anakinra and 2/3 taking DMARD were in remission.
  
  
  CONCLUSIONS
  Anakinra induced more beneficial responses than DMARD in patients with AOSD and was favored in the OLE phase. (ClinicalTrials.gov Protocol Registration NCT01033656).
authors.affiliation: Department of Medicine, Helsinki University Central Hospital and Helsinki University, Helsinki, Finland. dan.nordstrom@hus.fi
authors.forename: Dan
authors.initials: D
authors.lastname: Nordström
authors.forename: Ann
authors.initials: A
authors.lastname: Knight
authors.forename: Reijo
authors.initials: R
authors.lastname: Luukkainen
authors.forename: Ronald
authors.initials: R
authors.lastname: van Vollenhoven
authors.forename: Vappu
authors.initials: V
authors.lastname: Rantalaiho
authors.forename: Anna
authors.initials: A
authors.lastname: Kajalainen
authors.forename: Johan G
authors.initials: JG
authors.lastname: Brun
authors.forename: Anne
authors.initials: A
authors.lastname: Proven
authors.forename: Lotta
authors.initials: L
authors.lastname: Ljung
authors.forename: Hannu
authors.initials: H
authors.lastname: Kautiainen
authors.forename: Tom
authors.initials: T
authors.lastname: Pettersson
mesh_terms: D000328:Adult; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001379:Azathioprine / Q000627:therapeutic use; D005260:Female; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein / Q000627:therapeutic use*; D007555:Isoxazoles / Q000627:therapeutic use; D000077339:Leflunomide; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D017472:Receptors, Interleukin-1 / Q000037:antagonists & inhibitors*; D012074:Remission Induction; D016706:Still's Disease, Adult-Onset / Q000188:drug therapy*; D012460:Sulfasalazine / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents; D053590:Interleukin 1 Receptor Antagonist Protein; D007555:Isoxazoles; D017472:Receptors, Interleukin-1; D012460:Sulfasalazine; D000077339:Leflunomide; D001379:Azathioprine; D008727:Methotrexate